Pharma Catches a Break: Alzheimer's Drug Development Gets Rare Congressional Boost
This article was originally published in RPM Report
Executive Summary
Wyeth has been working hard to generate support for Alzheimer's drug development and easing FDA approval standards. One sign of success: a call to Capitol Hill for a friendly hearing.
You may also be interested in...
The Alzheimer's Divide
Issues of clinical trial design are at the forefront in Alzheimer's drug development. Researchers and investors are weighing the impact of late-stage failures, even as significant unknowns remain about disease mechanism and the correlation of biochemical markers and clinical effects. A fundamental question hangs over AD drug development, which is unique in many respects: in deciding how to move from Phase II into Phase III, what can you know and how can you know it?
Straight Talk from FDA: Wyeth R&D Head Reacts to Climate Change for NDA/BLA Reviews
Wyeth has had some tough times with FDA on its current crop of NDAs.Those experiences sent a team of senior execs down to FDA to find out what is up at the agency. What the execs heard was a call to action. The meeting "caused us at Wyeth to realize that we have to find a different way to operate." The current series of delays and rejections for important new drug applications is not a temporary situation for companies to ride out, but rather a sign of new regulatory
Straight Talk from FDA: Wyeth R&D Head Reacts to Climate Change for NDA/BLA Reviews
Wyeth has had some tough times with FDA on its current crop of NDAs.Those experiences sent a team of senior execs down to FDA to find out what is up at the agency. What the execs heard was a call to action. The meeting "caused us at Wyeth to realize that we have to find a different way to operate." The current series of delays and rejections for important new drug applications is not a temporary situation for companies to ride out, but rather a sign of new regulatory